Adtran expands ALM with deep PON assurance for FTTX network monitoring
12.7.2023 15:00:00 EEST | Business Wire | Press release
Adtran today announced the extension of its ALM infrastructure assurance solution, enabling simple and cost-efficient fiber monitoring of passive optical networks (PON). Already widely deployed in other types of network architecture, the technology now provides deep PON assurance, enabling communication service providers (CSPs) to monitor their entire PON infrastructure for any faults or degradation. Until today, assuring PON networks was challenging and expensive. Now there’s a simple and cost-efficient way to leverage real-time insight so that maintenance teams can quickly locate and resolve issues before they affect customers. PON networks are critical for the delivery of high-speed connectivity to millions of homes and businesses. The ability to comprehensively monitor this essential part of the network will deliver major benefits in terms of performance, reliability and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230712070000/en/
Adtran’s ALM deep PON assurance technology is a unique solution that will provide CSPs with granular insight into their PON networks. (Photo: Business Wire)
“The evolution of our ALM device to include deep PON assurance marks a major milestone for the industry and for our company. It’s the first time since the merger of Adtran and ADVA that our combined technology teams have released a solution that shows the close synergies between the organizations,” said Christoph Glingener, CTO of Adtran. “We are major players in both the PON and fiber assurance spaces with rapidly growing market shares. By utilizing our expertise in these areas, we’ve developed a unique solution that could have an enormous impact on CSPs’ opex costs. For the first time, they will be able to both monitor and manage their PON networks in one pane of glass. This will provide CSPs with more insight and granular control than ever before. And because our deep PON assurance technology works through splitters, we’re able to keep capex costs low.”
Adtran’s ALM technology for in-service fiber monitoring is available immediately and can be easily integrated into existing fiber-to-the-home, fiber-to-the-business or any other FTTX network. The non-intrusive, service-agnostic deep PON assurance solution eliminates the need for demarcation reflectors in the field, ensuring compatibility with any existing PON network while reducing operational complexity. Offering valuable insights into passive network quality, it acts like a radar to pinpoint the location of issues. Featuring fanless operation and low-power consumption, the ultra-compact ALM enhances operational efficiency and sustainability. CSPs can quickly check the status of their PON network through Adtran’s web-based GUI, Ensemble Controller network management platform or a dedicated mobile application for on-the-go access.
“Our ALM assurance platform is already recognized as the gold standard for fiber monitoring in optical networks. With our deep PON assurance innovation, we’re extending its benefits to many more customers, enabling FTTX network operators to dramatically shorten repair cycles and avoid unnecessary truck rolls. This breakthrough technology will transform how CSPs manage their PON infrastructure, enabling them to provide a better customer experience while reducing costs and improving sustainability,” commented Sander Jansen, GM of Infrastructure Monitoring at Adtran. “We’re excited to help our customers unlock the full potential of their PON networks and provide them with the real-time insights they need to optimize performance and reduce their carbon footprint.”
Further information on Adtran’s ALM deep PON assurance technology is available in these slides.
A supporting product video is also available to watch.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230712070000/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
